Home / Pharmaceuticals / Anaplastic Lymphoma Kinase Inhibitors Market By Molecule (Crizotinib, Ceritinib and Alectinib Hydrochloride) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Anaplastic Lymphoma Kinase Inhibitors Market By Molecule (Crizotinib, Ceritinib and Alectinib Hydrochloride) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Published: Jun 2019 | Report Code: 59740-06-19

Industry Outlook

The anaplastic lymphoma kinase (ALK) inhibitors market is set to reach from US$ 1,496.4 Mn in 2018 to 8,329.1 Mn by 2027 keen to demonstrate exuberating growth at a compounded annual growth rate (CAGR) of 21.2% during the forecast period from 2019 to 2027. Lung cancer is the second most occurring type of cancer in both men and women population worldwide. Increased consumption of tobacco, unhealthy lifestyle and stress are the major risk factor responsible for the occurrence of lung cancer. A strong drug pipeline of second and third generation ALK inhibitors being currently studied in various stages of clinical trials are being developed specifically for the treatment of non small cell lung cancer (NSCLC).

Market Synopsis

Anaplastic Lymphoma Kinase Inhibitors Market 

Get a sample copy for more information

"Excellent pharmacodynamic and pharmacokinetic properties drive the market growth of first generation ALK inhibitors"

Non small cell lung cancer (NSCLC) is the most common type of lung cancer occurring throughout the globe. The prognosis of the NSCLC is difficult and its initial screening is rather poor which significantly increases the requirement for development of targeted drug therapy for its treatment. FDA has approved only 2 drugs specifically for the treatment of NSCLC In the present scenario first generation ALK inhibitor Crizotinib is spearheading the molecule segment for anaplastic lymphoma kinase inhibitors market. It is basically an aminopyridine and piperidine derivative which selectively inhibits receptor tyrosine kinase and the ALK fusion proteins during the treatment of NSCLC. It has the potency to inhibit tumor cell growth. Alectinib hydrochloride is another first line ALK inhibitor which effectively inhibits wild type ALK point mutant variants and disrupts the tumor cell growth associated with advanced stage NSCLC.  Hence, excellent pharmacodynamic and pharmacokinetic properties together drive the market growth for first generation ALK inhibitors.

Anaplastic Lymphoma Kinase Inhibitors Market

Get a sample copy for more information

"Rising prevalence of lung cancer and affordable reimbursement scenario together drive the market growth in North America region"

Representing a share of 36.2% North America is currently leading the regional segment for anaplastic lymphoma kinase (ALK) inhibitors market. According to the research findings of American Society of Clinical Oncology (ASCO), in 2019, approximately 228,150 U.S. citizens have been reported to be suffering with lung cancer with a high prevalence rate in African American people. Affordable reimbursement scenario pertaining to the treatment of non small cell lung cancer drives the market growth ALK inhibitors in North America region. Europe is in the second place with 29.8% market share primarily due to huge prevalence rate of lung cancer in the European Union which is 54 per 100,000 people as brought forward by the 2018 statistical report of European Commission. Supportive regulatory environment provided by the European Medical Agency to expedite the clinical trials pertaining to second and third generation anaplastic lymphoma kinase inhibitors for the treatment of non small cell lung cancer  (NSCLC). Asia Pacific presently accounts for 15.5% market share and is keen to register outstanding growth during the forecast period on account of significant rise in tobacco consumption, thereby promoting the proliferation of NSCLC and developing healthcare infrastructure.

Anaplastic Lymphoma Kinase Inhibitors Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by molecule and by geography. 

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Molecule (2017–2027; US$ Mn)
 • Crizotinib
 • Ceritinib
 • Alectinib Hydrochloride

 Geography Segment (2017–2027; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Biopharmaceutical companies actively seeking to create a strong foothold in the anaplastic lymphoma kinase inhibitors market are Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC and Tesaro, Inc.

Key questions answered in this report

  • Which biopharmaceutical companies are engaged in the development of ALK inhibitors for the treatment of NSCLC?
  • What are the inorganic and organic market growth strategies adopted for the market assessment of anaplastic lymphoma kinase inhibitors market?
  • What is the disease etiology associated with NSCLC?
  • Why are the first line ALK inhibitors employed selectively for the treatment of NSCLC?
  • What is the prevalence rate of lung cancer in developing nation of Asia Pacific and Latin America regional segment?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Molecule
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global ALKI Market Portraiture
2.2. Global ALKI Market, by Molecule, 2018 (US$ Mn)
2.3. Global ALKI Market, by Geography, 2018 (US$ Mn)

Chapter 3. Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global ALKI Market, by Key Players, 2018

Chapter 4. Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market, by Molecule
4.1. Overview
4.2. Crizotinib
4.3. Ceritniib
4.4. Alectinib hydrochloride
4.5. Pipeline Analysis
4.5.1. Tabular Representation of Phase I and II Drug Pipeline

Chapter 5. Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market, by Geography
5.1. Overview
5.2. North America ALKI Market Analysis, 2017 – 2027
5.2.1. North America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.2.2. North America ALKI Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe ALKI Market Analysis, 2017– 2027
5.3.1. Europe ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.3.2. Europe ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific ALKI Market Analysis, 2017 – 2027
5.4.1. Asia Pacific ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America ALKI Market Analysis, 2017 – 2027
5.5.1. Latin America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.5.2. Latin America ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa ALKI Market Analysis, 2017 – 2027
5.6.1. MEA ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.6.2. MEA ALKI Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Betta Pharmaceuticals Co., Ltd.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Criterium, Inc.
6.3. F. Hoffman-La Roche Ltd.
6.4. Helsinn Therapeutics
6.5. Novartis AG
6.6. Oncoethix GmbH
6.7. Pfizer, Inc.
6.8. Takeda Pharmaceutical Co., Ltd.
6.9. Xcovery Holding Company, LLC
6.10. Tesaro, Inc.

* Here we are using ALKI as a short form of Anaplastic Lymphoma Kinase Inhibitors

FIG. 1 Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market: Research Methodology
FIG. 2 ALKI: Market Segmentation
FIG. 3 Global ALKI Market, by Molecule, 2018 (US$ Mn)
FIG. 4 Global ALKI Market, by Geography, 2018 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2018
FIG. 6 Competitive Analysis: Global ALKI Market, by Key Players, 2018
FIG. 7 Global Crizotinib Molecule Market for ALKI, 2017 – 2027 (US$ Mn)
FIG. 8 Global Ceritinib Molecule Market for ALKI, 2017 – 2027 (US$ Mn)
FIG. 9 Global Alectinib Hydrochloride Molecule Market for ALKI, 2017 – 2027 (US$ Mn)
FIG. 10 U.S. ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 11 Canada ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 12 U.K. ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 13 Germany ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 14 Rest of Europe ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 15 China ALKI Market, 2017– 2027 (US$ Mn)
FIG. 16 Japan ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 17 Rest of Asia Pacific ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 18 Brazil ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 19 Mexico ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 20 Rest of Latin America ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 21 GCC ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 22 Rest of Middle East and Africa ALKI Market, 2017 – 2027 (US$ Mn)

TABLE 1 Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market Portraiture
TABLE 2 Global ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 3 Global ALKI Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 North America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 5 North America ALKI Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 Europe ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 7 Europe ALKI Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 Asia Pacific ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East and Africa ALKI Market, by Molecule, 2017– 2027 (US$ Mn)
TABLE 13 Middle East and Africa ALKI Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 Betta Pharmaceuticals Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Criterium, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 F. Hoffman-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Helsinn Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Oncoethix GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Takeda Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Xcovery Holding Company, LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Tesaro, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients